'One dose of vaccine enough to keep cervical cancer away'
Mass vaccinationKenya is currently carrying out mass vaccination launched in October 2019 against the HPV virus where 800,000 school-going girls aged 10 years are targeted. The vaccination will be conducted in two phases - six months apart, of a dose each. This is meant to protect girls against HPV, increasing their immunity against cervical cancer, which kills 3,286 women every year and with 5,250 being diagnosed with the same in the country. HPV type 16 and 18 are responsible for up to 70 per cent of cervical cancers according to medical journal webmd.com while types 6 and 11 are known to cause genital warts (even in men) but rarely does this develop to cancer. In the latest study by Jama Network, a sample of 1,620 women with a mean age of 22 years participated. Out of the sample, 1,004 were unvaccinated while 616 received the jab. Of the 616, 106 received one dose, 126 received two doses and 384 received three doses. The study found out that the prevalence of the virus was 12.5 per cent among the unvaccinated lot. Among the vaccinated, the prevalence stood at 2.4 per cent among those with one dose; 5.1 per cent for those who had two doses and 3.1 per cent for those who had three doses. In figures: HPV type 6,11,16,18 was traced in 111 unvaccinated women, 14 who received three doses, seven who received two doses, and four who received one dose. For HPV types 31,33 and 45: 57 of the unvaccinated lot were infected, 22 in those who received three doses, three in those who received two doses and 11 in those who received one dose. Other high risk HPV types were traced in 254 unvaccinated women, 109 of those who received three doses, 34 in those who received two doses and 22 in those who had one dose. “There was no significant difference in prevalence for one dose versus two doses or one dose versus three doses,” explained the findings. It adds: “Difference(s) were not statistically significant for cross protection (except for two doses versus unvaccinated and one dose versus two doses) and other high risk HPV types.”
During trialsThe findings on the efficacy of the vaccine, the study reads, do support previous researches during trials of the HPV vaccine that compared its effectiveness with one, two and three doses. One limitation of this latest study, however, is that it did not consider the different times the women were vaccinated.
Do not miss out on the latest news. Join the Standard Digital Telegram channel HERE.